Accordingly, dichotomized Kaplan–Meier survival analysis was performed to further investigate how Vim+ or EpCAM+ CTCs and CTECs in all recruited NSCLC patients responded to bevacizumab combination therapy (Fig. 5C). This evidence concerns the gene VIM and non-small cell lung carcinoma.